Casma Therapeutics

With deep expertise in cellular degradation biology, Casma is advancing targeted therapies for neurodegeneration and beyond. X guidelines

[Casma Therapeutics @CasmaTx]

Can modulating lysosomal function change the way we treat #Parkinsons? Thanks to #TheGeneticsPodcast for hosting Casma’s CEO to break down the science behind TRPML1, #autophagy, and CSM-101, and what it could mean for the treatment of rare and common forms of PD.

[Sano Genetics @sanogenetics]

🎙️Tune in to Episode 193 of #TheGeneticsPodcast 🚀

This week, we’re joined by Frank Gentile, CEO of @CasmaTx. Patrick and Frank discuss the disruption of autophagy in neurodegenerative diseases and findings from Casma’s drug candidates targeting autophagy for GBA1-associated diseases.

#TheGeneticsPodcast #Autophagy #RareDisease

Available here👇

🎧 https://t.co/IBZ7KPP5Qy
📽️ https://t.co/D3PpK4pJOj

#genetics #SanoGenetics #genomics #PrecisionMedicine

[Casma Therapeutics @CasmaTx]

Casma Therapeutics has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist for Parkinson’s disease. Preclinical data to be presented at GBA1 Meeting 2025 in Montreal.

[https://t.co/4gq4zZxjJl

[Casma Therapeutics @CasmaTx]

Casma announces change in leadership.  Keith Dionne, Ph.D., has stepped down as CEO. Dr. Dionne will continue to serve on the BOD. Frank Gentile, Ph.D., formerly COO of Casma, has been appointed as the new CEO and will also serve on the BOD. Read more: https://t.co/TBWbECwb9t

[Casma Therapeutics @CasmaTx]

Casma closes a $46 M Series C financing with 6 new investors plus 100% commitment from existing investors. Funds will advance Casma’s drug development program in B-cell lymphoma. Read the press release: https://t.co/1B8JGciDKs

[Casma Therapeutics @CasmaTx]

@CasmaTx Scientific CoFounder @TheHurleyLab was recently inducted into the National Academy of Sciences @theNASciences -. A great recognition of his immense contributions to the field of structural membrane biology!

[Casma Therapeutics @CasmaTx]

@Casmatx CSO Leon Murphy will be presenting exciting data @GordonConf Lysosomes and Endocytosis meeting https://t.co/6FDUFKTx1h ! See you all at Proctor Academy, NH! #Autophagy #Lysosomes #Degradation @GordonConf

[Casma Therapeutics @CasmaTx]

Excited to be sharing Casma science with the Autophagy field at the GRC! So good to be together again! https://t.co/JOGffk830g

[Vinay Eapen🔬🧬🧫 @Post_Dogg]

Check out this nice feature in @Nature detailing some of the approaches biotech is taking in targeting #autophagy. @CasmaTx among those mentioned!
https://t.co/oWgo1OwfrG

[Casma Therapeutics @CasmaTx]

Casma’s Chief Medical Officer Dan Ory is co-leading the session on “Future Biomarker Considerations in NPC” https://t.co/LRFibDSq7w

[Casma Therapeutics @CasmaTx]

We are excited to be published in the Science Advances Journal on showcasing a novel mechanism related to TFEB activation and lysosomal biology. Read more here: https://t.co/qQi776PJwF @FloreyLab

[Casma Therapeutics @CasmaTx]

Casma supports Pride!

[Casma Therapeutics @CasmaTx]

Check out new Casma Science in collaboration with @FloreyLab @BrumellLab! GABARAP membrane conjugation sequesters the FLCN-FNIP tumor suppressor complex to activate TFEB and lysosomal biogenesis #mTOR #TFEB #autophagy #ATG8 #lysosomes https://t.co/gygcFOoGvS

[Casma Therapeutics @CasmaTx]

We are excited to announce the appointment of Nagesh Mahanthappa, PhD, MBA, to our Board of Directors. @NMahanthappa was most recently the founding CEO of @ScholarRock. Read the press release: https://t.co/grVEe6XBlo

[Casma Therapeutics @CasmaTx]

We are pleased to announce the completion of our $50 million Series B financing round, led by The Column Group (TCG). The financing adds new investors, including Eventide and @schroderadveq, as well as participation from @ThirdRockV. Learn more: https://t.co/h19lF9aN94

[Casma Therapeutics @CasmaTx]

We are proud to be named a #Fierce15 company by @FierceBiotech! This honor recognizes our terrific team and our bold science as we seek to harness autophagy to treat severe disease. Read more about our “fierce” approach to pioneering this new modality: https://t.co/iy7uVkUZSC

[Casma Therapeutics @CasmaTx]

Autophagy is a growing field with enormous potential across multiple disease areas. We're delighted to be featured in this #autophagy deep dive from @RLCScienceBoss for @cenmag: https://t.co/9vrKQIXiDC

[Casma Therapeutics @CasmaTx]

We're excited to announce receipt of a research grant from @MichaelJFoxOrg to advance our research into #autophagy-based therapies for #Parkinsons disease. Learn more: https://t.co/qxT6o1VmDm

[Casma Therapeutics @CasmaTx]

We're delighted to be one of @BosBizJournal's Best Places to Work for 2019! We’re proud of our company, our culture and most of all, our terrific team. https://t.co/yVnzvWs4Ao #Casmanians #BBJBPTW

[Casma Therapeutics @CasmaTx]

We’re very excited to establish our scientific advisory board with the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., whose diverse expertise will help guide our efforts to address disorders with high unmet need. Learn more: https://t.co/IBdMeIMm2h